Open | $0.178 |
Close | $0.150 |
Volume / Avg. | 655.684K / 8.657M |
Day Range | 0.150 - 0.189 |
52 Wk Range | 0.102 - 1.460 |
Market Cap | $5.543M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 31 |
Short Interest | 9.83% |
Days to Cover | 2.82 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Atreca (NASDAQ: BCEL) through any online brokerage.
Other companies in Atreca’s space includes: Alzamend Neuro (NASDAQ:ALZN), Virios Therapeutics (NASDAQ:VIRI), Imunon (NASDAQ:IMNN), BioRestorative Therapies (NASDAQ:BRTX) and NexImmune (NASDAQ:NEXI).
The latest price target for Atreca (NASDAQ: BCEL) was reported by Wedbush on Monday, August 14, 2023. The analyst firm set a price target for 1.00 expecting BCEL to rise to within 12 months (a possible 614.80% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Atreca (NASDAQ: BCEL) is $0.1399 last updated March 18, 2024 at 7:58 PM EDT.
There are no upcoming dividends for Atreca.
Atreca’s Q1 earnings are confirmed for Wednesday, May 8, 2024.
There is no upcoming split for Atreca.
Atreca is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.